Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling

Completed

• Conditions: Primary Disease

• Registration Number: NCT01323894
• Lead Sponsor: China Medical University Hospital

Brief Summary

The first year purpose:

The best concentration of canonical Wnt3a will be investigated in promoting the osteoblastogenesis of human mesenchymal stem cells.

Detailed Description

Our previous work is investigating the viral (Adv-BMP-2) administration for the development of a model to generate bones for possible use in clinical settings; the non-viral and viral administrations will be compared for best osteogenesis effects.

The first year purpose:

The best concentration of canonical Wnt3a will be investigated in promoting the osteoblastogenesis of human mesenchymal stem cells.

Study Timeline

• Study First Submitted: 2011-03-24
• Study First Submitted QC: 2011-03-25
• Study First Posted: 2011-03-28
• Study Start: 2011-08
• Primary Completion: 2012-08
• Study Completion: 2013-07
• Status Verified: 2016-06
• Last Update Submitted: 2016-06-15
• Last Update Posted: 2016-06-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

• age above 10 years old
• The patients require surgery ner iliac or abdomen areas

Exclusion Criteria

• age below 10 years old

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling/Hydroxyapatite Nanoparticles--Comparisons between Non-viral and Viral administration in Tissue Engineered Bone Regeneration	2 years	August 2011-July 2013

Trial Locations

Locations (1)

China Medical Universty Hospital; 🇨🇳 Taichung, Taiwan